ArticleBMC medical genomics2009
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.
Article in BMC medical genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Pooled it
- Prioritizing genes associated with prostate cancer development.BMC cancer · 2010Pooled it
- Asymmetric microarray data produces gene lists highly predictive of research literature on multiple cancer types.BMC bioinformatics · 2010Pooled it
- Loss of COL20A1 in Schwann Cells Alters Regeneration of the Neuromuscular Junction and Locomotor Activity in Mice.Journal of molecular neuroscience : MN · 2025Article
- Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors.International journal of molecular sciences · 2022Article
- Hsa-miR-183-5p Modulates Cell Adhesion by Repression ofNon-coding RNA · 2022Article
- The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis.Cancers · 2021Article
- Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.Urologic oncology · 2019Review
- Purification and Functional Characterization of the C-Terminal Domain of the β-Actin-Binding Protein AIM1 In Vitro.Molecules (Basel, Switzerland) · 2018Article
- AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.Nature communications · 2017Article
- Prognostic Utility of a New mRNA Expression Signature of Gleason Score.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.Oncotarget · 2015Article
- Imputation of TruncatedThe annals of applied statistics · 2014Article
- Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.The American journal of pathology · 2013Article
- Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.PloS one · 2013Article
- Androgen receptor-target genes in african american prostate cancer disparities.Prostate cancer · 2013Article
- Identification and characterization of alternative exon usage linked glioblastoma multiforme survival.BMC medical genomics · 2012Article
- RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.Cancers · 2012Article
- An empirical Bayesian approach for identifying differential coexpression in high-throughput experiments.Biometrics · 2012Article
- Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development.Journal of bioinformatics and computational biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe genetic mechanisms of prostate tumorigenesis remain poorly understood, but with the advent of gene expression array capabilities, we can now produce a large amount of data that can be used to explore the molecular and genetic mechanisms of prostate tumorigenesis.
methodsWe conducted a meta-analysis of gene expression data from 18 gene array datasets targeting transition from normal to localized prostate cancer and from localized to metastatic prostate cancer. We functionally annotated the top 500 differentially expressed genes and identified several candidate pathways associated with prostate tumorigeneses.
resultsWe found the top differentially expressed genes to be clustered in pathways involving integrin-based cell adhesion: integrin signaling, the actin cytoskeleton, cell death, and cell motility pathways. We also found integrins themselves to be downregulated in the transition from normal prostate tissue to primary localized prostate cancer. Based on the results of this study, we developed a collagen hypothesis of prostate tumorigenesis. According to this hypothesis, the initiating event in prostate tumorigenesis is the age-related decrease in the expression of collagen genes and other genes encoding integrin ligands. This concomitant depletion of integrin ligands leads to the accumulation of ligandless integrin and activation of integrin-associated cell death. To escape integrin-associated death, cells suppress the expression of integrins, which in turn alters the actin cytoskeleton, elevates cell motility and proliferation, and disorganizes prostate histology, contributing to the histologic progression of prostate cancer and its increased metastasizing potential.
conclusionThe results of this study suggest that prostate tumor progression is associated with the suppression of integrin-based cell adhesion. Suppression of integrin expression driven by integrin-mediated cell death leads to increased cell proliferation and motility and increased tumor malignancy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.